Helicobacter pylori (H. pylori) is a spiral-shaped gram-negative aerobic bacterium that grows in the digestive tract and has a tendency to infect the stomach. Bacteria play a vital role in balancing the stomach ecology. When H. pylori invades and attacks the stomach lining, it causes stomach infections. These infections can lead to peptic ulcers and gastritis. They are also associated with stomach, duodenal, and gastric cancers. These infections are commonly found in both men as well as women.
Over 50% of the world’s population is infected by H. pylori. In some countries, the prevalence of H. pylori is higher than 80%, making this infection one of the most common bacterial infections. In 1994, the WHO’s, International Agency for Research on Cancer classified H. pylori as a Class 1 carcinogen. The global Helicobacter pylori (H. pylori) non-invasive testing market was valued at US$ 518.0 Mn in 2017 and is estimated to reach a value of US$ 731.9 Mn by 2026, expanding at a CAGR of 3.99% during the forecast period.
Most people infected with Helicobacter pylori bacteria are unaware that they have been infected as the infection is mostly asymptomatic. Children are more susceptible to H. pylori infections. Patients suffering from peptic ulcers that are caused by H. pylori experience symptoms such as vomiting, abdominal pain, nausea, loss of appetite, and excessive burping. In some cases, peptic ulcers lead to severe complications such as obstruction in the stomach lining, internal bleeding, or perforation. High prevalence rates of H. pylori bacteria are projected to propel the global Helicobacter pylori (H. pylori) non-invasive testing market during the forecast period.
Developing countries reflect a higher prevalence percentage of H. pylori. Poor sanitation, lack of potable water supply, poor food hygiene, poor personal hygiene, and overcrowding are some of the key factors attributed to the spread of H. pylori infections. Rise in awareness regarding this infection among the global population is one of the factors propelling the expansion of the helicobacter pylori (H. pylori) non-invasive testing market. However, low diagnosis rates even in high prevalence geographies, asymptomatic nature of the infection, and stringent regulatory norms are expected to hamper the market.
The global helicobacter pylori (h. pylori) non-invasive testing market can be segmented based on test type, test method, end-user, and region. In terms of test type, the market can be classified into serology test, stool antigen test (SAT), and urea breath test (UBT). The serology test segment is expected to lose market share during the forecast.
Although the serology test method is quick, easy, and cost effective compared to other tests, regional agencies such as the American Gastroenterology Association (AGA) and National Health Services (NHS) have updated their guidelines to recommend stopping the use of serology testing for the detection of H. pylori due to its inaccurate nature. The urea breath test segment is estimated to constitute a significant market share by the end of the forecast period owing to the test’s accuracy and growing availability. Based on test method, the market can be categorized into laboratory-based tests and point-of-care tests.
Request for Sample Copy of Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=45312
The laboratory-based tests segment is expected to hold a dominant share by the end of 2026. In terms of end-user, the market can be classified into hospitals, clinics, and diagnostic laboratories. The diagnostic laboratories segment is anticipated to account for a major market share, followed by the hospitals segment. The rise in number of diagnostic laboratories can be attributed to a large number of tests being carried out in standalone and hospital-affiliated diagnostic laboratories owing to their ability to handle high volume of tests.
In terms of region, the global helicobacter pylori (h. pylori) non-invasive testing market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to lead the global market in the 2018-2026 period. The expansion of the market in the region can be attributed to the presence of key players in the region and swift technological advancements in the field of helicobacter pylori (h. pylori) non-invasive testing. Europe is expected to hold a prominent market share during the forecast period.
Key players operating in the global helicobacter pylori (h. pylori) non-invasive testing market are DiaSorin S.p.A., Meridian Bioscience, Inc., Exalenz Bioscience Ltd., Alere, Thermo Fisher Scientific, Biomerica, Inc., Certest Biotec S.L., Sekisui Diagnostics, CorisBioconcept SPRL, and Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd.